Hikma Pharmaceuticals PLC(Hikma) announced it has launched an authorized generic version of Jazz Pharmaceuticals' Xyrem®1 (sodium oxybate) oral solution CIII.Hikma will have 180 days of marketing exclusivity for its authorized generic product in the US. Sodium Oxybate oral solution, 0.5 g/mL is a prescription medicine used to treat the following symptoms in people 7 years of age or older with narcolepsy: sudden onset of weak or paralyzed muscles (cataplexy), excessive daytime sleepiness (EDS).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,837 GBX | +0.05% | +1.05% | +2.68% |
Jun. 24 | Teva launches generic version of Novo Nordisk's diabetes drug Victoza | RE |
Jun. 20 | Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position' | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.68% | 5.29B | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Hikma Launches Authorized Generic of Xyrem® (Sodium Oxybate) in the US